Search results for: 'Companion Diagnostics Partnering Terms & Agreements'

Companion Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2010 to 2024

Global Pharmaceutical Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter pharmaceutical partnering deals. 

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals.

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019 to 2024 report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Global Academic and Non-Profit Partnering Terms and Agreements 2019-2024 report provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. 

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the world's leading biopharma companies.

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 provides comprehensive understanding and unprecedented access to clinical stage partnering agreements entered into by the world's leading biopharma companies

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals